Regeneron Pharmaceuticals Valuation
Is 0R2M undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
6/6Valuation Score 6/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0R2M when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0R2M ($797.2) is trading below our estimate of fair value ($2237.89)
Significantly Below Fair Value: 0R2M is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0R2M?
Key metric: As 0R2M is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 0R2M's PE Ratio? | |
|---|---|
| PE Ratio | 18.1x |
| Earnings | US$4.65b |
| Market Cap | US$84.19b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5x |
| Enterprise Value/EBITDA | 14.9x |
| PEG Ratio | 2.2x |
Price to Earnings Ratio vs Peers
How does 0R2M's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 57x | ||
GNS Genus | 149.7x | 37.0% | UK£1.2b |
GSK GSK | 22x | 22.4% | UK£55.2b |
AZN AstraZeneca | 31.1x | 18.0% | UK£159.6b |
BVXP Bioventix | 25.3x | n/a | UK£204.9m |
0R2M Regeneron Pharmaceuticals | 18.1x | 8.1% | US$84.2b |
Price-To-Earnings vs Peers: 0R2M is good value based on its Price-To-Earnings Ratio (18.1x) compared to the peer average (57x).
Price to Earnings Ratio vs Industry
How does 0R2M's PE Ratio compare vs other companies in the European Biotechs Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: 0R2M is good value based on its Price-To-Earnings Ratio (18.1x) compared to the European Biotechs industry average (25.3x).
Price to Earnings Ratio vs Fair Ratio
What is 0R2M's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 18.1x |
| Fair PE Ratio | 31.2x |
Price-To-Earnings vs Fair Ratio: 0R2M is good value based on its Price-To-Earnings Ratio (18.1x) compared to the estimated Fair Price-To-Earnings Ratio (31.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$797.20 | US$1,082.63 +35.8% | 11.8% | US$1,230.00 | US$800.00 | n/a | 25 |
| Nov ’25 | US$841.93 | US$1,095.43 +30.1% | 11.1% | US$1,230.00 | US$800.00 | n/a | 25 |
| Oct ’25 | US$1,046.67 | US$1,157.67 +10.6% | 11.7% | US$1,300.00 | US$820.00 | n/a | 25 |
| Sep ’25 | US$1,183.76 | US$1,153.33 -2.6% | 12.0% | US$1,300.00 | US$805.00 | n/a | 25 |
| Aug ’25 | US$1,094.20 | US$1,119.01 +2.3% | 12.9% | US$1,300.00 | US$720.00 | n/a | 25 |
| Jul ’25 | US$1,051.58 | US$1,056.41 +0.5% | 12.1% | US$1,229.00 | US$720.00 | n/a | 25 |
| Jun ’25 | US$970.46 | US$1,047.65 +8.0% | 11.7% | US$1,185.00 | US$720.00 | n/a | 25 |
| May ’25 | US$897.37 | US$1,038.08 +15.7% | 11.2% | US$1,189.00 | US$720.00 | n/a | 25 |
| Apr ’25 | US$966.21 | US$1,022.19 +5.8% | 11.3% | US$1,184.00 | US$710.00 | n/a | 25 |
| Mar ’25 | US$984.92 | US$1,009.93 +2.5% | 11.8% | US$1,184.00 | US$710.00 | n/a | 23 |
| Feb ’25 | US$961.21 | US$968.35 +0.7% | 11.8% | US$1,125.00 | US$710.00 | n/a | 24 |
| Jan ’25 | US$877.30 | US$919.76 +4.8% | 11.6% | US$1,125.00 | US$700.00 | n/a | 24 |
| Dec ’24 | US$812.87 | US$908.57 +11.8% | 10.7% | US$1,066.00 | US$680.00 | n/a | 25 |
| Nov ’24 | US$793.24 | US$902.36 +13.8% | 10.6% | US$1,064.00 | US$680.00 | US$841.93 | 23 |
| Oct ’24 | US$823.14 | US$898.87 +9.2% | 10.5% | US$1,050.00 | US$680.00 | US$1,046.67 | 23 |
| Sep ’24 | US$835.52 | US$895.61 +7.2% | 10.8% | US$1,050.00 | US$665.00 | US$1,183.76 | 23 |
| Aug ’24 | US$734.13 | US$857.78 +16.8% | 10.6% | US$1,045.00 | US$650.00 | US$1,094.20 | 23 |
| Jul ’24 | US$710.27 | US$862.87 +21.5% | 11.7% | US$1,045.00 | US$650.00 | US$1,051.58 | 23 |
| Jun ’24 | US$738.13 | US$883.78 +19.7% | 10.9% | US$1,050.00 | US$650.00 | US$970.46 | 23 |
| May ’24 | US$804.10 | US$878.61 +9.3% | 10.5% | US$1,040.00 | US$650.00 | US$897.37 | 23 |
| Apr ’24 | US$818.61 | US$871.83 +6.5% | 10.9% | US$1,040.00 | US$650.00 | US$966.21 | 23 |
| Mar ’24 | US$767.34 | US$830.78 +8.3% | 12.2% | US$1,011.00 | US$605.00 | US$984.92 | 23 |
| Feb ’24 | US$756.54 | US$806.78 +6.6% | 12.5% | US$1,023.00 | US$605.00 | US$961.21 | 23 |
| Jan ’24 | US$712.54 | US$801.04 +12.4% | 13.0% | US$1,027.00 | US$595.00 | US$877.30 | 23 |
| Dec ’23 | US$767.39 | US$795.83 +3.7% | 13.3% | US$1,027.00 | US$575.00 | US$812.87 | 23 |
| Nov ’23 | US$764.08 | US$780.78 +2.2% | 13.4% | US$1,025.00 | US$575.00 | US$793.24 | 23 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Laboratorios Farmaceuticos Rovi
€3.3b
Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.
0ILL
€65.15
7D
-1.8%
1Y
30.4%
hVIVO
UK£182.0m
Operates as a pharmaceutical service and contract research company in the United Kingdom.
HVO
UK£0.27
7D
-2.2%
1Y
44.6%
Hikma Pharmaceuticals
UK£4.0b
Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.
HIKL
UK£17.96
7D
0.1%
1Y
3.9%